Astragaloside IV attenuates sepsis-induced intestinal barrier dysfunction via suppressing RhoA/NLRP3 inflammasome signaling

• AS-Ⅳ alleviated abnormal permeability and TJ expression of gut induced by sepsis. • AS-Ⅳ inhibited RhoA/NLRP3 inflammasome signaling activated by sepsis. • AS-Ⅳ attenuated gut barrier impairment by suppressing RhoA/NLRP3 inflammasome.